Short answer
ClearPoint Neuro, Inc. (CLPT) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $11M (up 18.1% year over year) with net income of −$11M.
Q2 2026 key financials · XBRL
- Revenue
- $11M
- +18.1% YoY · −10.3% QoQ
- Net income
- −$11M
- −94.2% YoY · −18.7% QoQ
- Operating margin
- -94.2%
- Gross margin
- 61.7%
- EPS (diluted)
- −$0.38
- −90.0% YoY · −18.8% QoQ
Source: XBRL data from the ClearPoint Neuro, Inc. (CLPT) Q2 2026 10-Q on SEC EDGAR. USD.
ClearPoint Neuro, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New CAL facility risk triggered by preclinical CRO expansion and significant capital investment
- Most material update: CAL build-out and commissioning exposed to construction delays, cost overruns, equipment constraints, and vendor failures
- Compliance risk: inability to achieve or maintain GLP standards could prevent GLP studies and delay revenue
- Near-term operating risk: insufficient customer demand or delayed statements of work could leave CAL capacity underutilized
- Financial risk: fixed and variable CAL costs may exceed facility revenue, preventing an adequate investment return
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ClearPoint Neuro, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.